Fifty-one Stage @ predialysis CKD patients with hemoglobin < @ g/dL were randomly assigned to receive two period treatments with AST-@ plus once-monthly administration of continuous EPO receptor activator ( CERA , A ) and CERA alone ( B ) , with a @-week washout period in between .